Pearson, R. M. published the artcileBiochemical and hematological changes induced by tienilic acid combined with propranolol in essential hypertension, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, the main research area is tienilate propranolol essential hypertension.
In a double blind crossover trial, in which 16 patients with essential hypertension received placebo, tienilic acid (I) [40180-04-9] (250 mg/day), propranolol (II) [525-66-6] (80 mg twice daily), or I (250 mg/day) combined with II (80 mg twice daily), average blood pressure in the lying position was 169/98, 157/94, 159/90, and 142/86 mm Hg for placebo, I-, II-, and I combined with II-treated patients, resp. Thus, the effects of I and II on blood pressure were additive, and no interactions between I and II were observed I reduced serum water from 0.33 to 0.18 mmol/L and induced hypokalemia which was corrected by II. Basophil count and Hb were lower after I treatment than they had been at the start of the study.
Lancet published new progress about Essential hypertension. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.
Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem